No Data
No Data
Jefferies Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $20
Cogent Biosciences | 10-K: FY2024 Annual Report
Cogent Biosciences | 8-K: Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Cogent Biosciences: $312 M Sufficient to Fund Ops Well Past Clinical Readouts, Into Late 2026 >COGT
Cogent Biosciences: Top-line Results From SUMMIT Trial in NonAdvSM Patients Expected July >COGT
Cogent Biosciences: APEX Trial Enrollment in AdvSM Patients Complete; Top-Line Results Expected in 2H
Unlock the Full List
Peasant Investor OP : Shit this was a wrong trade, whale exited initial position